Back to Search Start Over

Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.

Authors :
Robbins HA
Ferreiro-Iglesias A
Waterboer T
Brenner N
Nygard M
Bender N
Schroeder L
Hildesheim A
Pawlita M
D'Souza G
Visvanathan K
Langseth H
Schlecht NF
Tinker LF
Agalliu I
Wassertheil-Smoller S
Ness-Jensen E
Hveem K
Grioni S
Kaaks R
Sánchez MJ
Weiderpass E
Giles GG
Milne RL
Cai Q
Blot WJ
Zheng W
Weinstein SJ
Albanes D
Huang WY
Freedman ND
Kreimer AR
Johansson M
Brennan P
Source :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Nov 01; Vol. 40 (31), pp. 3613-3622. Date of Electronic Publication: 2022 Jun 14.
Publication Year :
2022

Abstract

Purpose: Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown.<br />Methods: We constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6 serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population rates of OPC and mortality.<br />Results: The nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw and diagnosis and 5,794 controls. The estimated 10-year OPC risk for HPV16-E6 seropositive males at age 50 years was 17.4% (95% CI, 12.4 to 28.6) and at age 60 years was 27.1% (95% CI, 19.2 to 45.4). Corresponding 5-year risk estimates were 7.3% and 14.4%, respectively. For HPV16-E6 seropositive females, 10-year risk estimates were 3.6% (95% CI, 2.5 to 5.9) at age 50 years and 5.5% (95% CI, 3.8 to 9.2) at age 60 years and 5-year risk estimates were 1.5% and 2.7%, respectively. Over 30 years, after a seropositive result at age 50 years, an estimated 49.9% of males and 13.3% of females would develop OPC. By contrast, 10-year risks among HPV16-E6 seronegative people were very low, ranging from 0.01% to 0.25% depending on age, sex, and smoking status.<br />Conclusion: We estimate that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC, with 10-year risks of 17%-27% for males and 4%-6% for females age 50-60 years in the United States. This high level of risk may warrant periodic, minimally invasive surveillance after a positive HPV16-E6 serology test, particularly for males in high-incidence regions. However, an appropriate clinical protocol for surveillance remains to be established.

Details

Language :
English
ISSN :
1527-7755
Volume :
40
Issue :
31
Database :
MEDLINE
Journal :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publication Type :
Academic Journal
Accession number :
35700419
Full Text :
https://doi.org/10.1200/JCO.21.01785